BRAF and melanoma: This result does not infer that MEK is an inappropriate therapeutic target; to the contrary, it infers that as with BRAF mutated melanomas treated with BRAF inhibitors, a subpopulation of melanoma cells survive and lie dormant prior to reoccurrence.